126 related articles for article (PubMed ID: 26321049)
1. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.
Marin JJ; Briz O; Rodríguez-Macias G; Díez-Martín JL; Macias RI
Blood Rev; 2016 Jan; 30(1):55-64. PubMed ID: 26321049
[TBL] [Abstract][Full Text] [Related]
2. Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Medeiros BC
Acta Haematol; 2014; 131(4):200-1. PubMed ID: 24296429
[No Abstract] [Full Text] [Related]
3. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
5. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
6. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
Krogh-Madsen M; Bender B; Jensen MK; Nielsen OJ; Friberg LE; Honoré PH
Cancer Chemother Pharmacol; 2012 May; 69(5):1155-63. PubMed ID: 22212298
[TBL] [Abstract][Full Text] [Related]
8. Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Su YZ; Wang CB; Zhou Y; Sun NT
Genet Mol Res; 2015 May; 14(2):5181-7. PubMed ID: 26125711
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Erikci AA; Ozturk A; Tekgunduz E; Sayan O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):E14-5. PubMed ID: 19717372
[TBL] [Abstract][Full Text] [Related]
10. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
[No Abstract] [Full Text] [Related]
11. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia.
Pallis M; Russell N
Leukemia; 2004 Dec; 18(12):1927-30. PubMed ID: 15483678
[No Abstract] [Full Text] [Related]
12. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
14. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Beck JD
Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
17. [Results of treating acute myeloid leukemia resistant to conventional chemotherapy with moderately large doses of cytarabine and etoposide].
Robak T; Krykowski E; Matusewicz W; Brodowski L; Hołub A; Drzewoski J
Pol Tyg Lek; 1988 Nov; 43(47):1508-11. PubMed ID: 3075284
[No Abstract] [Full Text] [Related]
18. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60).
Kachalaki S; Baradaran B; Majidi J; Yousefi M; Shanehbandi D; Mohammadinejad S; Mansoori B
Biomed Pharmacother; 2015 Oct; 75():100-4. PubMed ID: 26463638
[TBL] [Abstract][Full Text] [Related]
19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
20. Assessment of drug resistance in acute myeloid leukemia.
Funato T; Harigae H; Abe S; Sasaki T
Expert Rev Mol Diagn; 2004 Sep; 4(5):705-13. PubMed ID: 15347263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
